The Story Behind BioSkepsis: Rethinking Biomedical Discovery

Our Story

BioSkepsis is a product of EFEVRE TECH LTD, a biotechnology company founded in 2018 in Larnaca, Cyprus, specialising in laboratory automation and digitalisation for life-science laboratories. Our mission was to build more than just another search tool; we set out to create an evidence-grounded research engine capable of translating over 40 million peer-reviewed papers into actionable laboratory insights. By prioritizing mechanistic depth over generic summaries, we help Academic Principal Investigators, Early-Career Researchers, Biotech R&D teams, and Pharmaceutical Industries to navigate the frontier of biomedical discovery without the risk of AI hallucinations.

After years of developing hardware robotics (AMGEL) and laboratory software (VITALE) for molecular and genetic workflows, we observed a critical bottleneck in the scientific lifecycle: the transition from data generation to data synthesis. While our robots could accelerate physical experiments, researchers remained "manual" in their literature review process, struggling to keep pace with an exponential surge in publications.

BioSkepsis was born from that gap. Building on our heritage in laboratory automation and digitalisation, we applied the same precision required for robotics to the challenge of synthesising biomedical literature. The name "Skepsis" comes from the Greek word for critical examination, because we believe every scientific claim deserves scrutiny, not blind acceptance.

What BioSkepsis Does: Evidence Funneling & Literature Synthesis

BioSkepsis is an AI-powered evidence engine engineered to solve the crisis of reproducibility and information overload in the life-sciences. By integrating Retrieval-Augmented Generation (RAG) with a biology-native knowledge graph, we transform 40M+ unstructured papers into structured, traceable, and decision-ready scientific intelligence.

At the core of our platform is Evidence Funneling: a multi-layered computational process that filters millions of peer-reviewed publications into focused, citation-backed insights. Unlike generic LLMs that provide surface-level summaries, BioSkepsis maps the mechanistic connective tissue between genes, molecular pathways, and clinical phenotypes. This allows researchers to visualize causal relationships and identify exactly where evidence holds or where scientific consensus breaks down.

Whether you are a PhD Candidate validating a novel hypothesis, an Academic Principal Investigator synthesising literature for a grant proposal, a Regulatory Expert assembling an HTA dossier, or a VC Analyst performing scientific due diligence on a biotech startup — BioSkepsis provides decision-grade evidence reducing the research lifecycle from weeks to minutes.

Contact the BioSkepsis Team

Whether you are interested in a technical deep dive or seeking a partnership to advance AI-driven biomedical discovery, our team is ready to assist. We bridge the gap between technical expertise and scientific curiosity.